$AURX
Nuo Therapeutics Inc Stock $aurx

$aurx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000143774923032632 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$197.0K	$232.2K
YoY Change	166.24%	507.17%
Cost Of Revenue	$41.37K	$53.82K
YoY Change	225.24%	728.61%
Gross Profit	$155.7K	$178.4K
YoY Change	154.0%	461.87%
Gross Profit Margin	79.0%	76.83%
Selling, General & Admin	$807.8K	$968.0K
YoY Change	-21.15%	2.58%
% of Gross Profit	518.95%	542.52%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.770K	$3.672K
YoY Change	36.1%	35.85%
% of Gross Profit	2.42%	2.06%
Operating Expenses	$807.8K	$968.0K
YoY Change	-21.15%	2.58%
Operating Profit	-$652.1K	-$789.5K
YoY Change	-32.3%	-13.42%
Interest Expense	-$1.050K	-$1.087K
YoY Change	22.09%	17.64%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$1.087K
YoY Change	-100.0%	17.64%
Pretax Income	-$653.2K	-$790.6K
YoY Change	-31.93%	-13.38%
Income Tax
% Of Pretax Income
Net Earnings	-$653.2K	-$790.6K
YoY Change	-31.93%	-13.38%
Net Earnings / Revenue	-331.52%	-340.44%
Basic Earnings Per Share		-$0.02
Diluted Earnings Per Share	-$0.02	-$0.02
COMMON SHARES
Basic Shares Outstanding	42.32M	42.32M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$928.7K	$582.6K
YoY Change	-54.73%	-79.75%
Cash & Equivalents	$928.7K	$582.6K
Short-Term Investments
Other Short-Term Assets	$174.5K	$233.3K
YoY Change	-30.6%	-10.32%
Inventory	$209.6K	$209.7K
Prepaid Expenses
Receivables	$250.7K	$232.9K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.563M	$1.258M
YoY Change	-40.66%	-63.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.08K	$48.85K
YoY Change	-15.2%	-4.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$314.4K	$341.4K
YoY Change	-23.76%	-20.94%
TOTAL ASSETS
Total Short-Term Assets	$1.563M	$1.258M
Total Long-Term Assets	$314.4K	$341.4K
Total Assets	$1.878M	$1.600M
YoY Change	-38.38%	-58.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$394.5K	$400.9K
YoY Change	-0.8%	19.96%
Accrued Expenses	$188.6K	$196.1K
YoY Change	53.01%	639.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$674.5K	$685.3K
YoY Change	12.34%	56.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$164.2K	$187.9K
YoY Change	-35.75%	-31.97%
Total Long-Term Liabilities	$164.2K	$187.9K
YoY Change	-35.75%	-31.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$674.5K	$685.3K
Total Long-Term Liabilities	$164.2K	$187.9K
Total Liabilities	$838.7K	$873.2K
YoY Change	-2.02%	22.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.90M	-$29.30M
YoY Change	11.57%	13.57%
Common Stock	$4.424K	$4.232K
YoY Change	5.84%	1.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.039M	$726.7K
YoY Change
Total Liabilities & Shareholders Equity	$1.878M	$1.600M
YoY Change	-38.38%	-58.6%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$653.2K	-$790.6K
YoY Change	-31.93%	-13.38%
Depreciation, Depletion And Amortization	$3.770K	$3.672K
YoY Change	36.1%	35.85%
Cash From Operating Activities	-$671.4K	-$796.4K
YoY Change	-18.29%	-21.03%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$2.760K
YoY Change	-100.0%	-27.37%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$2.760K
YoY Change	-100.0%	-172.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	962.5K	1.035M
YoY Change		107.0%
NET CHANGE
Cash From Operating Activities	-671.4K	-796.4K
Cash From Investing Activities	0.000	2.760K
Cash From Financing Activities	962.5K	1.035M
Net Change In Cash	291.1K	241.4K
YoY Change	-135.23%	-147.12%
FREE CASH FLOW
Cash From Operating Activities	-$671.4K	-$796.4K
Capital Expenditures	$0.00	-$2.760K
Free Cash Flow	-$671.4K	-$793.6K
YoY Change	-18.75%	-21.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42316516
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42316516
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41799016
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41799016
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	89312	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	337226	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-28443
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	23-3011702
	dei	Entity Address Address Line1 EntityAddressAddressLine1	8285 El Rio, Suite 190
	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77054
	dei	City Area Code CityAreaCode	346
	dei	Local Phone Number LocalPhoneNumber	396-4770
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42316516
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	582589	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2051208	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	55000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	55000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	232879	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	92320	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	209660	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	240005	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	178340	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	196378	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1258468	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2634911	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48850	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53165	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	292584	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	359284	usd
CY2023Q3	us-gaap	Assets Assets	1599902	usd
CY2022Q4	us-gaap	Assets Assets	3047360	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	400884	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	397703	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	196093	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	123275	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	88291	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	79453	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	685268	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	600431	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	187912	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	255592	usd
CY2023Q3	us-gaap	Liabilities Liabilities	873180	usd
CY2022Q4	us-gaap	Liabilities Liabilities	856022	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	4232	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4180	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30005576	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28951963	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29283086	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26764805	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	726722	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2191338	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1599902	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3047360	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	232241	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	38250	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	53818	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6495	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	178423	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	31755	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	967976	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	943620	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	967976	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	943620	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-789533	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-911865	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1087	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-924	usd
CY2023Q3	aurx	Gain On Settlement Of Legacy Accounts Payable GainOnSettlementOfLegacyAccountsPayable	0	usd
CY2022Q3	aurx	Gain On Settlement Of Legacy Accounts Payable GainOnSettlementOfLegacyAccountsPayable		usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1087	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-924	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-790640	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-912789	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42142141
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41134252
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	411510	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	38250	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	84724	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6495	usd
	us-gaap	Gross Profit GrossProfit	326786	usd
	us-gaap	Gross Profit GrossProfit	31755	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2842955	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2389164	usd
	us-gaap	Operating Expenses OperatingExpenses	2842955	usd
	us-gaap	Operating Expenses OperatingExpenses	2389164	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2516169	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2357409	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2112	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1248	usd
	aurx	Gain On Settlement Of Legacy Accounts Payable GainOnSettlementOfLegacyAccountsPayable	0	usd
	aurx	Gain On Settlement Of Legacy Accounts Payable GainOnSettlementOfLegacyAccountsPayable	146438	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2112	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	145190	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2518281	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2212219	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41914648
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39395195
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2191338	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2420	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-855755	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1338003	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4718	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-871886	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	470835	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1035000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11527	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-790640	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	726722	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	792839	usd
CY2022Q1	aurx	Stockholders Equity Issuance Of Options To Settle Related Party Compensation Liabilities StockholdersEquityIssuanceOfOptionsToSettleRelatedPartyCompensationLiabilities	103333	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6430	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-375380	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	527222	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3957757	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1082	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-924050	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3562011	usd
CY2022Q3	aurx	Stock Issued During Period Value Common Shares Participation Rights And Contingent Warrants StockIssuedDuringPeriodValueCommonSharesParticipationRightsAndContingentWarrants	500000	usd
CY2022Q3	aurx	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1436	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-912789	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3150658	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2518281	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2212219	usd
	us-gaap	Depreciation Depreciation	11560	usd
	us-gaap	Depreciation Depreciation	4059	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	18665	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8948	usd
	aurx	Gain On Settlement Of Accounts Payable GainOnSettlementOfAccountsPayable	-0	usd
	aurx	Gain On Settlement Of Accounts Payable GainOnSettlementOfAccountsPayable	146438	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	16074	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	66700	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	45973	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	240560	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30400	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-14272	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	264844	usd
	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-18038	usd
	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	153827	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3180	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-45946	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	72819	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-16667	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-58842	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-73079	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2496375	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2884440	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7244	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	55343	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7244	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55343	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1035000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3957757	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1035000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4457757	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1468619	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1517974	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2106208	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1414569	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	637589	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2932543	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2051208	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1414569	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	55000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2106208	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1414569	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	582589	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2877543	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	55000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	55000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	637589	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2932543	usd
	us-gaap	Interest Paid Net InterestPaidNet	2112	usd
	us-gaap	Interest Paid Net InterestPaidNet	324	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	aurx	Issuance Of Options To Settle Accrued Compensation Liabilities IssuanceOfOptionsToSettleAccruedCompensationLiabilities	0	usd
	aurx	Issuance Of Options To Settle Accrued Compensation Liabilities IssuanceOfOptionsToSettleAccruedCompensationLiabilities	103333	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	426538	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Description of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Description of Business</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a Delaware corporation organized in <em style="font: inherit;">1998</em> under the name Informatix Holdings, Inc. In <em style="font: inherit;">1999,</em> Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In <em style="font: inherit;">2000,</em> Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In <em style="font: inherit;">2001,</em> Cytomedix, filed for bankruptcy under Chapter <em style="font: inherit;">11</em> of the United States Bankruptcy Code, after which Cytomedix was authorized to continue to conduct its business as a debtor and debtor-in-possession. Cytomedix emerged from bankruptcy in <em style="font: inherit;">2002</em> under a Plan of Reorganization. In <em style="font: inherit;"> September 2007, </em>Cytomedix received <em style="font: inherit;">510</em>(k) clearance for the Aurix System (“Aurix”), formerly known as the AutoloGel™ System, from the U. S. Food and Drug Administration (“FDA”). In <em style="font: inherit;"> April 2010, </em>Cytomedix acquired the Angel Whole Blood Separation System (“Angel”) and the Angel Business, from Sorin Group USA, Inc. In <em style="font: inherit;"> February 2012, </em>Cytomedix, acquired Aldagen, Inc. (“Aldagen”), a privately held developmental cell-therapy company located in Durham, NC. In <em style="font: inherit;">2014,</em> Cytomedix changed its name to Nuo Therapeutics, Inc. In <em style="font: inherit;">2016,</em> Nuo filed for and emerged from bankruptcy under Chapter <em style="font: inherit;">11.</em> Effective <em style="font: inherit;"> May 1, 2019, </em>we furloughed our remaining employees and ceased standard operational activities as we awaited developments concerning our reconsideration request with the Centers for Medicare & Medicaid Services (“CMS”) regarding Medicare coverage for Aurix. Based on a favorable National Coverage Determination issued in <em style="font: inherit;"> April 2021, </em>we initiated restart activities for the business beginning in <em style="font: inherit;"> October 2021 </em>and the Aurix product was available for commercial sale beginning <em style="font: inherit;"> May 2022 </em>with limited commercial revenues initiated in the <em style="font: inherit;">third</em> quarter <em style="font: inherit;">2022.</em> Aldagen is a non-operational, wholly owned subsidiary of Nuo.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i> <span style="text-decoration: line-through; "> Impact of COVID- <em style="font: inherit;">19</em> Pandemic on Financial Statements </span></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> <span style="text-decoration: line-through; "> On <em style="font: inherit;"> March 11, 2020, </em>the World Health Organization declared the outbreak of COVID- <em style="font: inherit;">19</em> as a </span>“ <span style="text-decoration: line-through; "> pandemic </span>” <span style="text-decoration: line-through; "> , or a worldwide spread of a new disease. Many countries imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses. </span> <span style="text-decoration: line-through; "> On <em style="font: inherit;"> May 5, 2023, </em>the World Health Organization declared that COVID- <em style="font: inherit;">19</em> <em style="font: inherit;">no</em> longer constitutes a public health emergency. </span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> <span style="text-decoration: line-through; "> The extent to which COVID- <em style="font: inherit;">19</em> <em style="font: inherit;"> may </em>impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The unaudited condensed consolidated financial statements do <em style="font: inherit;">not</em> include any adjustments that might result from the outcome of this uncertainty. </span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> <span style="text-decoration: line-through; "> The Company has <em style="font: inherit;">not</em> experienced any significant negative impact on its <em style="font: inherit;"> June 30, 2023 </em>unaudited condensed consolidated financial statements related to COVID- <em style="font: inherit;">19.</em> </span> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29300000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	600000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Use of Estimates</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but <em style="font: inherit;">not</em> limited to stock-based compensation, recoverability and depreciable lives of long-lived assets, deferred taxes, and associated valuation allowance. Actual results could differ from those estimates.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Credit Concentration</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We generate accounts receivable from the sale of our products. Specific customer receivable balances in excess of <em style="font: inherit;">10%</em> of total receivables at <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;"> December 31, 2022 </em>is listed below.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>September 30,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>2023</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>December 31, </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">19%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer B</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">10%</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">17%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer C</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">16%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer D</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">14%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer E</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">12%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer F</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">12%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer G</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">10%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> less than <em style="font: inherit;">10%</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Revenue from significant customers exceeding <em style="font: inherit;">10%</em> of total revenues for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>is listed below. All our revenue for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>was generated within the U.S.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Three</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Months </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>September 30,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>2023</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Months </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>September 30,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer B</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">14%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">12%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer G</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">14%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">11%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer H</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">12%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">10%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Historically, we used single suppliers for several components of the Aurix® product line. We outsource the manufacturing of various product components to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is <em style="font: inherit;">no</em> assurance that <em style="font: inherit;">one</em> or more of them will <em style="font: inherit;">not</em> experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of Aurix are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.</p>
CY2023Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	600000	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	16000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	116000	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	94000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	157000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	83000	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	16000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0165	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4726667
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4626667
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	454901	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	447657	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	406051	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	394492	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48850	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53165	usd
CY2023Q3	us-gaap	Depreciation Depreciation	3672	usd
CY2022Q3	us-gaap	Depreciation Depreciation	2703	usd
	us-gaap	Depreciation Depreciation	11560	usd
	us-gaap	Depreciation Depreciation	4059	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	450000
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	450000
CY2023Q3	aurx	Authorized Shares Common And Preferred AuthorizedSharesCommonAndPreferred	101000000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11527	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1436	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18665	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8948	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	80000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	89312	usd
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	337226	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	39400	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	38900	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	118200	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	49500	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	27345	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	112833	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	80273	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	82705	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	21284	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	324440	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	48237	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	276203	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	88291	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	187912	usd

Files In Submission

Name	View Source	Status
aurx-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001437749-23-032632-index-headers.html	Edgar Link	pending
0001437749-23-032632-index.html	Edgar Link	pending
0001437749-23-032632.txt	Edgar Link	pending
0001437749-23-032632-xbrl.zip	Edgar Link	pending
aurx-20230930.xsd	Edgar Link	pending
aurx20230930_10q.htm	Edgar Link	pending
ex_596446.htm	Edgar Link	pending
ex_596447.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
aurx-20230930_cal.xml	Edgar Link	unprocessable
aurx-20230930_pre.xml	Edgar Link	unprocessable
aurx-20230930_lab.xml	Edgar Link	unprocessable
aurx20230930_10q_htm.xml	Edgar Link	completed
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AURX
Nuo Therapeutics Inc Stock $aurx

2023 Q4 Form 10-Q Financial Statement

#000143774923032632 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AURX Nuo Therapeutics Inc Stock $aurx

2023 Q4 Form 10-Q Financial Statement

#000143774923032632 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AURX
Nuo Therapeutics Inc Stock $aurx